Skip to content Skip to footer
Subscribe Now
Exclusive_Barbara Klencke_2022
EXCLUSIVE

Barbara Klencke, CMO at Sierra Oncology (now GSK) Shares Insights on the Significant benefits obtained from the Pivotal Myelofibrosis Study

Shots: Barbara gave a comprehensive view of the P-III (MOMENTUM) clinical study results which evaluates its lead candidate in myelofibrosis Sierra is now acquired by GSK (completed on 1st July 2022) resulting in GSK commercializing this prime product once approved The interview outlines Sierra’s (now GSK) vision to develop transformative therapies for rare cancers Smriti: Thank…
July 18, 2022

Read more

PharmaShots Interview In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility
VIEWPOINTS

PharmaShots Interview: In Conversation with Caris Life Sciences’, CBO, Brian Lamon, Where he Shares Insights on Opening of New Liquid Biopsy Laboratory Facility

Shots: Brian spoke about opening of its new liquid biopsy lab in Phoenix, AZ and an investment of $45M for the development of its facilities Brian also talked about the establishment of lab will enhance company’s molecular profiling capabilities and launch of a blood-based diagnostic assay The interview gives a view of how Caris Life…
July 4, 2022

Read more

PharmaShots Interview In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022
VIEWPOINTS

PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022

Shots Mai-Britt talked about the P-I/II clinical trial data and study design of its lead candidate in metastatic melanoma in an e-poster presentation at AACR 2022 She also spoke about IO Biotech’s unique platform with tumor defense mechanisms to kill cancer cells The interview gives a profound understanding of how IO Biotech is advancing to…
June 28, 2022

Read more

PharmaShots Interview In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect
VIEWPOINTS

PharmaShots Interview: In Conversation with Leonard A. Farber and James Welsh, Where they Share Insights on How Nanoparticle can Trigger an Immune Priming Effect

Shots: Leonard spoke about the newly developed radiotherapy-activated nanoparticle and other cancer therapies developing in Nanobiotix’s pipeline James shared his views on the data presented at the 2022 Annual Meeting of the American Association of Cancer Research The interview provides a core understanding of Nanobiotix’s outlook to expand the utility of nanoparticles in cancer treatment…
June 15, 2022

Read more